Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma

References

• Flores LT, Bennett AV, Law EB, et al. Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5(4):119–124.
   PubMedGoogle Scholar
• Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–909.
   PubMed Web of Science ®Google Scholar
• Jagsi R, Griffith KA, Boike TP, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015;1(7):918–930.
   PubMed Web of Science ®Google Scholar
• Kaae JK, Johnsen L, Hansen CR, et al. Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. Acta Oncol. 2019;58(10):1366–1372.
   PubMed Web of Science ®Google Scholar
• Hunter KU, Schipper M, Feng FY, et al. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013;85(4):935–940.
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–198.
   PubMed Web of Science ®Google Scholar
• Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.
   PubMedGoogle Scholar
• Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88(9):2164–2171.
   PubMed Web of Science ®Google Scholar
• Moro C, Brunelli C, Miccinesi G, et al. Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer. 2006;14(1):30–37.
   PubMed Web of Science ®Google Scholar
• Hui D, Titus A, Curtis T, et al. Implementation of the Edmonton Symptom Assessment System for symptom distress screening at a community cancer center: a pilot program. Oncologist. 2017;22(8):995–1001.
   PubMed Web of Science ®Google Scholar
• Silvoniemi M, Vasankari T, Loyttyniemi E, et al. Symptom assessment for patients with non-small cell lung cancer scheduled for chemotherapy. Anticancer Res. 2016;36(8):4123–4128.
   PubMed Web of Science ®Google Scholar
• Johnstone PAS, Lee J, Zhou JM, et al. A modified Edmonton Symptom Assessment Scale for symptom clusters in radiation oncology patients. Cancer Med. 2017;6(9):2034–2041.
   PubMed Web of Science ®Google Scholar
• Keller J, Fiala MA, Slade M, et al. Presenting characteristics and symptom burden of newly diagnosed older multiple myeloma patients in the compass study. Blood. 2015;126(23):3307–3307.
   Google Scholar
• Buzaglo JS, Miller MF, Karten C, et al. Symptom burden and palliative care for patients with multiple myeloma: Cancer Experience Registry findings. JCO. 2015;33(29_suppl):81–81.
   Web of Science ®Google Scholar
• Seitzler S, Finley-Oliver E, Simonelli C, et al. Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol. 2019;12(6):419–424.
   PubMed Web of Science ®Google Scholar
• Jordan K, Proskorovsky I, Lewis P, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22(2):417–426.
   PubMed Web of Science ®Google Scholar
• Bubis LD, Davis LE, Canaj H, et al. Patient-reported symptom severity among 22,650 cancer outpatients in the last 6 months of life. J Pain Symptom Manage. 2020;59(1):58–66.e4.
   Google Scholar
• Castelli R, Sciara S, Lambertenghi Deliliers G, et al. Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study. Ann Hematol. 2017;96(5):779–786.
   PubMed Web of Science ®Google Scholar
• Reeder-Hayes KE, Mayer SE, Olshan AF, et al. Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study. Cancer. 2019;125(22):3985–3992.
   PubMed Web of Science ®Google Scholar
• McCall MK, Connolly M, Nugent B, et al. Symptom experience, management, and outcomes according to race and social determinants including genomics, epigenomics, and metabolomics (SEMOARS + GEM): an explanatory model for breast cancer treatment disparity. J Cancer Educ. 2020;35(3):428–440.
   PubMed Web of Science ®Google Scholar
• Naghavi AO, Echevarria MI, Strom TJ, et al. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol. 2016;45:18–25.
   PubMed Web of Science ®Google Scholar
• Kamal AH, Bull J, Wolf SP, et al. Unmet needs of African Americans and Whites at the time of palliative care consultation. Am J Hosp Palliat Care. 2017;34(5):461–465.
   PubMed Web of Science ®Google Scholar